Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Price:
1.87 HKD
1.08%
Market Closed
Updated:
May 19, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
-1
Current
-3.7
Median
4.6
Industry
Higher
than median
Lower
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=-1
Enterprise Value
/
452m
EBITDA
-408.2m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| CN |
|
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
|
1.5B HKD | -1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
293.9B USD | 13.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
167.6B USD | 18.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115B USD | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.2B USD | 22.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.3B AUD | 22.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.4B USD | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
50.9B USD | -9.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -61.9 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.6B USD | 14.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.7T KRW | 45.3 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
-0.9
2-Years Forward
EV/EBITDA
-0.8
3-Years Forward
EV/EBITDA
-1
You don't have any saved screeners yet
